Unfortunately our stock is somehow not well understood by the markets. The market compares us with generic companies. We need to look at Biocon as a bellwether stock. A stock that is differentiated, a stock that is focused on R&D, and a very-very strong balance sheet with huge value drivers at the end of it.
I'm ultimately not so much of a professor as a progresser. And I'm ready to move away from what I consider to be this weird mid-century dream that I feel pulls us as a country, and us as a culture, backward.